Maha FDA shortlists 59 pharmacists for selling Remdesivir

Published On 2020-10-24 07:06 GMT   |   Update On 2020-10-24 07:06 GMT

Mumbai: The Maharashtra government on Friday came out with a list of 59 pharmacists in the state where Remdesivir, a drug used for COVID-19 treatment, will be available at Rs 2,360 per unit.Principal secretary of the public health department Dr Pradeep Vyas informed district collectors and municipal commissioners about the decision in a letter."The medicine is administered free of cost at...

Login or Register to read the full article

Mumbai: The Maharashtra government on Friday came out with a list of 59 pharmacists in the state where Remdesivir, a drug used for COVID-19 treatment, will be available at Rs 2,360 per unit.

Principal secretary of the public health department Dr Pradeep Vyas informed district collectors and municipal commissioners about the decision in a letter.

"The medicine is administered free of cost at state- run hospitals, however, there was no cap on its price at private hospitals.

"(Now) The pharmaceutical shops in every district and city are designated for its supply, which will ensure smooth supply of the medicine to every patient," Vyas said in the letter.

Read also: Gilead, European Commission Ink Pact For 500000 Treatment Courses Of Remdesivir Against COVID-19

"The Food and Drug Administration has shortlisted the pharmaceutical outlets in the state. There are five outlets in Mumbai division, 13 in Pune division, nine in Nashik, 11 in Aurangabad, 10 in Konkan, six in Nagpur and five in Amravati," the letter said.

Read also: FDA approves remdesivir for treating hospitalized COVID-19 patients



Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News